on MEDIAN TECHNOLOGIES (EPA:ALMDT)
Median Technologies Showcases AI Lung Cancer Diagnostic at RSNA 2024
Median Technologies has announced its participation in the RSNA 2024 Annual Meeting in Chicago. The event will be held from December 1-5. The company will demonstrate their AI-powered diagnostic software, eyonis™ LCS, designed to enhance early lung cancer screening. Located at booth #5442, Median's teams will present their latest advancements.
A peer-reviewed scientific e-poster and an AI Theater presentation are among the highlights. These sessions will explore the capabilities of eyonis™ LCS in comparison to radiologists, and its potential to boost global lung cancer screening programs. Earlier this year, eyonis™ LCS met significant milestone endpoints in its REALITY clinical trial.
The company plans to file for marketing authorization in the US and Europe by the first half of 2025, following results from a second pivotal study. Median Technologies aims to establish their diagnostic device as a critical tool in the fight against lung cancer.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDIAN TECHNOLOGIES news